| abstract |
The present invention relates to new variant osteoprotegerin (OVP) proteins, which demonstrate reduced binding affinity for their TRAIL ligand, when compared to wild-type osteoprotegerin. Nucleic acids are also provided which encode these OVPs. Recombinant vectors and host cells expressing these OVPs are also encompassed as are methods to produce recombinant OVPs. The present invention also relates to compositions comprising these OVPs, and to methods for treating bone diseases characterized by loss and / or increased bone change. The OVPs of the invention are used to prevent bone resorption and can be used to treat any condition that results in bone loss or abnormal bone change, such as osteoporosis, hypercalcemia, Paget's disease of bone, multiple myeloma, bone cancer and bone loss due to rheumatoid arthritis or osteomyelitis, and the like. |